Shanghai-based biotech Allist Pharmaceuticals Co., Ltd. (SHA: 688578) has received clearance from the National Medical Products Administration (NMPA) in China to commence a Phase I clinical study of its AST2169 liposome. This study will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of AST2169 in patients with advanced solid tumors harboring the KRAS G12D mutation.
AST2169 is a selectively developed inhibitor targeting the KRAS G12D mutation, which is prevalent in various cancers, including non-small cell lung cancer, colorectal cancer, and pancreatic cancer. Notably, there are currently no KRAS G12D inhibitors approved for marketing worldwide, positioning Allist at the forefront of innovation in this critical area of oncology.- Flcube.com
